DGX — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-07-23

• Senior Notes Offering and Repayment of Existing Senior Notes

• In May 2026, we completed a senior notes offering consisting of $500 million aggregate principal amount of 5.00% senior notes due June 2036 (the "2036 Senior Notes"), which were issued at an original issue discount of $6 million. On June 1, 2026, the net proceeds from the 2036 Senior Notes and cash …

• For further details see Note 7 to the interim unaudited consolidated financial statements.

• •pre-tax charges of $4 million ($1 million recorded in cost of services and $3 million recorded in selling, general and administrative expenses), or $0.04 per diluted share, primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and int…

• •pre-tax charges of $1 million, principally recorded in other operating expense (income), net, or $0.02 per diluted share, primarily representing a loss associated with the increase in the fair value of the contingent consideration accrual associated with previous acquisitions; partially offset by

Text removed vs the prior filing · source: 10-Q · 2026-04-22

• Equity in earnings of equity method investees, net of taxes$4 $18 $(14)(77.5)%

• Net income attributable to Quest Diagnostics$252 $220 $32 14.4 %

• Diluted earnings per common share attributable to Quest Diagnostics' common stockholders$2.24 $1.94 $0.30 15.5 %

• •pre-tax charges of $7 million, principally recorded in equity in earnings of equity method investees, net of taxes, or $0.05 per diluted share, representing the losses associated with changes in the carrying value of our strategic investments;

• •pre-tax charges of $7 million ($1 million recorded in cost of services and $6 million recorded in selling, general and administrative expenses), or $0.04 per diluted share, primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and int…

Text added vs the prior filing · source: 10-Q · 2026-07-23

• Net income attributable to Quest Diagnostics$320 $282 $572 $502

• Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans(20)(18)(38)

• The accompanying notes are an integral part of these statements.

• For the Three Months Ended June 30, 2025Quest Diagnostics Stockholders’ Equity

• For the Six Months Ended June 30, 2025Quest Diagnostics Stockholders’ Equity

Text removed vs the prior filing · source: 10-Q · 2026-04-22

• Treasury stock, at cost; 51 shares and 52 shares as of March 31, 2026 and December 31, 2025, respectively

• The Company is engaged in a multi-year program called Invigorate, which includes structured plans to drive savings and improve productivity across the value chain, including in such areas as patient services, logistics and laboratory operations, revenue services, information technology and procureme…

• The Company's pre-tax restructuring charges for the three months ended March 31, 2026 and 2025 were $7 million and $11 million, respectively, entirely related to employee separation costs associated with various workforce reduction initiatives as the Company continued to restructure its organization…

• In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass Memorial Medical Center ("UMass") on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020. As of March …

• The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses approximate fair value based on the short maturities of these instruments. As of March 31, 2026 and December 31, 2025, the fair value of the Company’s debt was estimated at $5.6 billion …

Text added vs the prior filing · source: 10-Q · 2026-07-23

• * Includes shares of common stock to be released from (a) stock options and/or restricted stock units that are expected to vest and/or (b) performance share awards that may vest, subject to the satisfaction of the applicable performance metrics. The actual number of shares of common stock that will …

Text removed vs the prior filing · source: 10-Q · 2026-04-22

• * Includes shares of common stock to be released from stock options.